
|Videos|March 23, 2021
Psychedelic Wellness
Author(s)Matt Stang
Early studies find psilocybin shows promise for some psychiatric disorders...
Advertisement
With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.
To learn more on psilocybin and earn CME credit, see
Mr Stang is the founder of
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Advertisement
Advertisement
Trending on Psychiatric Times
1
Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia
2
AI in 2025: A Look Back With Allen Frances, MD
3
Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics
4
Psychiatry and Artificial Intelligence in 2025
5




